Malignant eccrine spiradenoma: a meta-analysis of reported cases

Andreoli, Michael T.; Itani, Kamal M.F.

doi:10.1016/j.amjsurg.2010.04.015

Cited by 53 publications

(97 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Malignant eccrine spiradenoma is an extremely rare tumour and usually originates from benign eccrine spiradenoma, but sometimes develops de novo [3,11]. In the present patient, there was no history of benign eccrine spiradenoma before the development of malignant tumour.…”

Section: Discussionmentioning

confidence: 68%

“…These cells may express cytokeratins, epithelial membrane antigen (EMA), p53 and S100. Malignant transformation usually includes invasion of tumour cells into adjacent stroma [3,4]. In the present patient, immunohistochemical analysis of biopsy specimens showed a positive immunohistochemical staining with keratin, actin, EMA (Fig.…”

Section: Discussionmentioning

confidence: 93%

“…The typical clinical manifestation of MES is a chronic skin mass with recent rapid growth, which may show erythema, ulceration, bleeding and satellite nodules [3]. Malignant eccrine spiradenoma may occur in any location with a slight predominance in the trunk and extremities [1,11].…”

Section: Discussionmentioning

confidence: 99%

“…Malignant eccrine spiradenoma (MES) is one of the extremely rare sweat gland tumours and often arises from benign eccrine spiradenoma or, less commonly, may develop de novo [1,3]. Transformation into malignant form generally occurs 20 to 30 years after initial detection, with a latency period ranging from 6 to 70 years [3][4][5]. Malignant eccrine spiradenoma occurs predominantly in older patients regardless of the ethnic group, with a slight female predominance [4,5].…”

Section: Introductionmentioning

confidence: 99%

“…The nodules are often tender and occasionally painful [2]. Malignant eccrine spiradenoma (MES) is one of the extremely rare sweat gland tumours and often arises from benign eccrine spiradenoma or, less commonly, may develop de novo [1,3]. Transformation into malignant form generally occurs 20 to 30 years after initial detection, with a latency period ranging from 6 to 70 years [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

De novo malignant eccrine spiradenoma and metachronous lung cancer

Ünal¹,

Taşdemi̇r²,

Oguz³

et al. 2014

View full text Add to dashboard Cite

Malignant eccrine spiradenoma is an extremely rare sweat-gland tumour. Herein we aimed to present an 81-yearold woman with malignant eccrine spiradenoma repeated on the thigh and metachronous lung cancer. She presented with a palpable swelling in the right thigh region. Her systemic screening was normal and excisional biopsy was performed. A diagnosis of malignant eccrine spiradenoma was made. Thirty-two months later, the tumour recurred in the same region. The tumour was excised again. Lymph node metastasis was also detected in lymph node dissection. Fifteen months later, the tumour recurred again in the same place. In addition, lymph node metastasis and bone metastasis were found. Palliative radiotherapy was performed for the involvement of the right femur. The treatment for metachronous lung cancer could not be given because of the patient's age and performance, and she could not be given additional treatment for the same reasons.

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

De novo malignant eccrine spiradenoma and metachronous lung cancer

Ünal¹,

Taşdemi̇r²,

Oguz³

et al. 2014

View full text Add to dashboard Cite

show abstract

Tumours of Skin Appendages

Calonje

2016

Rook's Textbook of Dermatology, Ninth Edition

View full text Add to dashboard Cite

This chapter on cutaneous appendageal tumours covers the spectrum of lesions displaying eccrine, apocrine, sebaceous and follicular differentiation. It includes cysts, hamartomas and benign and malignant tumours. Traditionally, appendageal tumours have been classified according to rigid criteria separating lesions with eccrine, apocrine, sebaceous and follicular differentiation. This separation is clearly artificial and it is now acknowledged that lesions regarded as strictly eccrine may well have apocrine differentiation and lesions classified as purely follicular may exhibit apocrine differentiation reflecting the close embryological relationship between the pilosebaceous unit and the apocrine gland.

show abstract

Tumours of Skin Appendages

Calonje,

Marušić

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

The clinical presentation of skin appendage tumours for the most part is not as specific and diverse as the histological features of this extremely heterogeneous tumour group. Differential diagnosis of certain appendageal tumours can be extremely subtle, yet greatly influence final treatment outcome. Occasional association of certain entities with inherited tumour syndrome s can be extremely important in terms of hereditary cancer screening. This chapter aims to provide the most important clinical, histological and genetic features for selected, most important cutaneous appendage tumours.

show abstract

Malignant eccrine spiradenoma: a meta-analysis of reported cases

Cited by 53 publications

References 43 publications

De novo malignant eccrine spiradenoma and metachronous lung cancer

De novo malignant eccrine spiradenoma and metachronous lung cancer

Tumours of Skin Appendages

Tumours of Skin Appendages

Contact Info

Product

Resources

About